Research library
Ultragenyx Pharmaceutical Inc. (RARE): the bull case and the bear case
Ultragenyx Pharmaceutical Inc. · NASDAQ · Equity · Stock
The synthesis
Robust commercial revenue growth and high gross margins are offset by a catastrophic Phase 3 trial failure and a strained balance sheet.
- Strong Commercial Execution
Trailing twelve-month revenue reached $716.9 million, representing 17.5% year-over-year growth driven by Crysvita sales in Latin America (10-Q, 2026-08-05).
- High-Margin Product Portfolio
The company maintains an 83.1% gross margin, indicating a highly profitable commercial platform once products transition from development to market.
- Near-Term Pipeline Catalysts
Management highlighted imminent potential launches for two gene therapies, DTX-401 and UX-111, as primary drivers for the company's path to profitability in 2027.
- Strategic Cost Realignment
A restructuring plan implemented in February 2026 aims to reduce operating expenses and focus resources on high-value clinical drivers (10-Q, 2026-08-05).
- Major Clinical Setback
The Phase 3 Aspire study for Angelman syndrome failed to meet primary or secondary endpoints, forcing a review of the entire program (8-K, 2026-09-02).
- Severe Operational Cash Burn
Despite revenue gains, the firm recorded a -73.8% operating margin and a -68.3% free cash flow margin, reflecting significant ongoing losses.
- Strained Financial Position
With $1.1 billion in net debt against a $1.4 billion market cap, the company faces a history of operating losses and needs additional capital (10-Q, 2026-08-05).
- Technical Breakdown
The stock is trading at $14.83, significantly below its 52-week low of $18.29 and all major moving averages, indicating a pronounced downtrend.
Catalysts
- DTX-401 BLA Submission Near-term
- UX-111 Regulatory Filing Near-term
- Angelman Program Review Ongoing
- Q3 Earnings Release Nov 2026
Risks
- Clinical Trial Failure Phase 3 Aspire
- Liquidity Risk $1.1B Net Debt
- Operating Losses -73.8% Margin
- Concentration Risk Crysvita Reliance
What would change the view
A shift toward a more constructive outlook would require successful BLA filings and subsequent approvals for DTX-401 and UX-111 to diversify the commercial portfolio and offset the Angelman syndrome setback. Conversely, the thesis would deteriorate further if the current cost-cutting measures fail to significantly narrow operating losses or if the company is forced into a highly dilutive capital raise to service its $1.1 billion debt load.
Insider activity
Open-market purchases and sales reported by company insiders on SEC Form 4, from EDGAR. Share counts and dates only.
Trailing 3 months: 0 open-market purchases by 0 insiders and 5 sales by 3 insiders. Net selling (Moderate — 3 insiders selling).
| Insider | Role | Side | Shares | Trade date | Filing |
|---|---|---|---|---|---|
| Horn Howard | Officer · Chief Financial Officer | Sale | 4,698 | 2026-07-01 | Form 4 |
| Horn Howard | Officer · Chief Financial Officer | Sale | 4,696 | 2026-08-03 | Form 4 |
| Sanders Corazon (Corsee) D. | Director | Sale | 2,000 | 2026-06-15 | Form 4 |
| Parschauer Karah Herdman | Officer · EVP and Chief Legal Officer | Sale | 1,900 | 2026-08-03 | Form 4 |
| Parschauer Karah Herdman | Officer · EVP and Chief Legal Officer | Sale | 1,899 | 2026-06-15 | Form 4 |
Sources
- FMP · RARE daily prices and technical indicators Analyst note
- FMP · RARE financial statements (income / balance / cash flow) SEC filing
- SEC EDGAR · RARE full-text filing search SEC filing
- SEC · 8-K filed 2026-09-02 (Items 8.01) SEC filing · 8-K · 2026-09-02
- SEC · 8-K filed 2026-08-19 (Items 8.01) SEC filing · 8-K · 2026-08-19
- SEC · SCHEDULE 13G filed 2026-08-14 SEC filing · SCHEDULE 13G · 2026-08-14
- SEC · SCHEDULE 13G filed 2026-08-13 SEC filing · SCHEDULE 13G · 2026-08-13
- SEC · 8-K filed 2026-08-11 (Items 8.01) SEC filing · 8-K · 2026-08-11
- SEC · SCHEDULE 13G filed 2026-08-07 SEC filing · SCHEDULE 13G · 2026-08-07
- SEC · 10-Q filed 2026-08-05 SEC filing · 10-Q · 2026-08-05
- SEC · 8-K filed 2026-08-04 (Items 2.02, 9.01) SEC filing · 8-K · 2026-08-04
- SEC · 4 filed 2026-08-04 SEC filing · 4 · 2026-08-04
- SEC · 4 filed 2026-08-04 SEC filing · 4 · 2026-08-04
- SEC · 144 filed 2026-08-03 SEC filing · 144 · 2026-08-03
- SEC · SCHEDULE 13G/A filed 2026-07-31 SEC filing · SCHEDULE 13G/A · 2026-07-31
- SEC · SCHEDULE 13G filed 2026-07-31 SEC filing · SCHEDULE 13G · 2026-07-31
- SEC · SCHEDULE 13G/A filed 2026-07-30 SEC filing · SCHEDULE 13G/A · 2026-07-30
- SEC · 4 filed 2026-07-06 SEC filing · 4 · 2026-07-06
- SEC · 144 filed 2026-07-01 SEC filing · 144 · 2026-07-01
- SEC · 4 filed 2026-06-15 SEC filing · 4 · 2026-06-15
- SEC · 4 filed 2026-06-15 SEC filing · 4 · 2026-06-15
- SEC · 144 filed 2026-06-15 SEC filing · 144 · 2026-06-15
- SEC · 144 filed 2026-06-15 SEC filing · 144 · 2026-06-15
- SEC · S-8 filed 2026-06-12 SEC filing · S-8 · 2026-06-12
- Benzinga · Ultragenyx Forced To Cut Costs After Disappointing Phase 3 Results News
- Barrons · Ultragenyx Stock Sinks 47% on Drug Trial Failure. Why Wall Street Isn't Giving Up Yet. News
- Reuters · Ultragenyx shares crater after Angelman syndrome drug fails late-stage trial News
- GlobeNewsWire · Ultragenyx Announces Phase 3 Aspire results in Angelman Syndrome News
- GlobeNewsWire · Ultragenyx Announces the Publication of a Successful 96-Week Randomized, Placebo-Controlled Trial with Crossover Treatme News
- Zacks Investment Research · 4 Rare Disease Drugmakers With Strong Long-Term Growth Prospects News
Read the full analysis in the app
This page publishes the written thesis. The app adds the sections not published here:
- Fundamentals
- Technicals
- News with bull, bear, and neutral tags
- 7-day news sentiment and earnings-call tone
- Forward analyst estimates
- Earnings-call summary
